VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
LNSR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
LNSRLENSAR, Inc.
$5.72$69M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksLNSRCash Flow

LENSAR, Inc. (LNSR) Cash Flow Statement

8Y historyFree accessUpdated daily

Free cash flow remains consistently negative, highlighted by a $4.3M outflow in 2026Q1, which underscores the company's inability to achieve self-sustaining operational scale.

LNSR Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Cash from Operations-12.16M-14.83M-2.27M-9.66M-14.86M-8.97M-13.79M-12.59M-1.89M
Operating CF Margin %--25.38%-4.25%-22.91%-42.02%-26.03%-52.27%-41.24%-7.73%
Operating CF Growth %-288.37%-551.91%76.45%34.98%-65.64%34.96%-9.55%-567.85%-
Net Income29.4M-34.28M-31.4M-14.38M-19.91M-19.6M-19.77M-14.66M-12.59M
Depreciation & Amortization4.56M4.5M3.93M3.52M3.41M2.76M2.56M3.87M4.59M
Stock-Based Compensation2.49M3.14M2.67M5.54M6.61M6.87M9.04M102K1.32M
Deferred Taxes00000527K57K-78K0
Other Non-Cash Items-26.81M10.7M25.58M3.45M618K517K505K537K9.15M
Working Capital Changes-4.38M1.1M-3.04M-7.78M-5.58M-42K-6.19M-2.36M5.92M
Change in Receivables2.39M289K-2.1M1.08M-1.44M-2.65M1.33M14K443K
Change in Inventory-11.21M-13.9M-4.9M-7.46M-6.89M2.33M-8.7M-4.77M-876K
Change in Payables7.34M12.99M1.96M-1.42M2.73M213K910K127K663K
Cash from Investing4.75M1.28M-2.16M-4.16M-115K-354K-326K-2.09M-3.89M
Capital Expenditures-77K-83K-156K-236K-115K-354K-366K-2.09M-3.25M
CapEx % of Revenue0.13%0.14%0.29%0.56%0.33%1.03%1.39%6.84%13.32%
Acquisitions00000040K0-644K
Investments---------
Other Investing00000000-644K
Cash from Financing358K10.26M78K19.76M-1.99M361K50M15.95M6.96M
Debt Issued (Net)00000012.4M13.22M3.5M
Equity Issued (Net)677K258K58K13.88M408K361K39.46M3.83M3.87M
Dividends Paid000000-1.86M-31K-198K
Share Repurchases000000000
Other Financing-319K10M20K5.88M-2.4M00-1.07M-214K
Net Change in Cash-7.05M-3.29M-4.36M5.95M-16.96M-8.96M35.88M1.27M1.18M
Free Cash Flow-12.24M-14.91M-2.43M-9.89M-14.97M-9.32M-14.16M-14.68M-5.13M
FCF Margin %-21.21%-25.52%-4.54%-23.47%-42.34%-27.06%-53.66%-48.08%-21.05%
FCF Growth %-202.4%-513.49%75.43%33.91%-60.58%34.15%3.55%-185.95%-
FCF per Share-0.79-1.25-0.21-0.90-1.47-0.99-1.29-1.38-4.80
FCF Conversion (FCF/Net Income)-0.42x0.43x0.07x0.67x0.75x0.46x0.70x0.86x0.15x
Interest Paid000000000
Taxes Paid42K42K24K18K3K19K000

Key Metrics

Growth RegimeDecelerating
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Liquidity and capital runway

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Quality Remains Highly Volatile

As reported in recent financial filings, the relationship between net income and operating cash flow is erratic, highlighted by a 2026Q1 net income of $36.3M against a negative $4.3M in operating cash flow, suggesting significant non-cash distortions or accounting anomalies that obscure true operational performance.

The extreme divergence between reported net income and cash generation indicates that earnings are not currently a reliable proxy for the company's ability to fund its own operations. Investors should monitor whether these accounting swings represent one-time adjustments or a structural disconnect between accrual-based reporting and actual cash collection.

Free Cash Flow Remains Consistently Negative

Based on quarterly cash flow statements, LENSAR has struggled to maintain positive free cash flow, with the most recent period showing a $4.3M outflow, reflecting a persistent inability to generate self-sustaining cash despite the ongoing commercial rollout of the ALLY platform across the United States.

The recurring negative free cash flow trajectory suggests that the company's current business model is heavily reliant on external financing to cover its operating deficits. This trend warrants further investigation into whether the cost of customer acquisition for the ALLY system will ever reach a point of cash-flow neutrality.

Working Capital Swings Impede Liquidity

According to historical cash flow data, working capital changes have been highly inconsistent, including a significant $8.6M outflow in 2026Q1, which suggests that the company is facing challenges in managing its cash conversion cycle as it scales its medical device manufacturing and distribution operations.

The volatility in working capital appears to be a primary driver of the company's erratic cash position, potentially indicating inefficiencies in inventory management or delays in collecting payments from surgical centers. Such fluctuations may indicate that the company's growth is consuming cash faster than it can be recovered.

Stock-Based Compensation Masks Cash Burn

As indicated by the provided financial statements, stock-based compensation remains a consistent non-cash expense, averaging roughly $700K per quarter, which effectively masks the true extent of the company's cash burn by reducing the reported net loss without impacting the actual cash balance available for operations.

While stock-based compensation is a standard practice for growth-stage medical device firms, its persistence in the face of negative operating cash flow suggests that the company is relying on equity dilution to preserve its limited cash runway. This practice may indicate that the underlying business is not yet generating sufficient cash to attract or retain talent without significant equity-based incentives.

LNSR — Frequently Asked Questions

Quick answers to the most common questions about buying LNSR stock.

How much cash does LENSAR, Inc. (LNSR) generate from operations?

LENSAR, Inc. (LNSR) generated $-14.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is LENSAR, Inc.'s free cash flow?

LENSAR, Inc. (LNSR) reported negative free cash flow of $14.9M in 2025, indicating capital requirements exceeded cash from operations.

What is LENSAR, Inc.'s capital expenditure (CapEx)?

LENSAR, Inc. (LNSR) spent $0.1M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.